产品描述: | PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research |
靶点: |
EC50: 216 nM (α7 nAChR);AChR |
体外研究: |
PNU-120596 increases agonist-evoked calcium flux mediated by an engineered variant of the human α7 nAChR. Electrophysiology studies confirme that PNU-120596 increases peak agonist-evoked currents mediated by wild-type receptors and also demonstrates a pronounced prolongation of the evoked response in the continued presence of agonist. PNU-120596 increases the channel mean open time of α7 nAChRs. When applied to acute hippocampal slices, PNU-120596 increases the frequency of ACh-evoked GABAergic postsynaptic currents measured in pyramidal neurons. PNU-120596 enhances agonist-evoked gating of nicotinic receptors by eliciting conformational effects that are similar but nonidentical to the gating conformations promoted by ACh. |
体内研究: |
PNU-120596 (1 mg/kg; intravenous injection; once) treatment improves the auditory gating deficit caused by Amphetamine in rats, a model proposed to reflect a circuit level disturbance associated with schizophrenia. When administered before carrageenan, NU-120596 (30 mg/kg; i.p.) significantly reduces mechanical hyperalgesia and weight-bearing deficits for up to 4 h in Sprague-Dawley rats. PNU-120596 attenuates the carrageenan-induced increase in levels of TNF-α and IL-6 within the hind paw oedema Animal Model: Male Sprague Dawley rats (250-300 g) treated with Amphetamine Dosage: 1 mg/kg Administration: Intravenous injection; once Result: Improved the auditory gating deficit caused by Amphetamine. |
细胞实验: |
Cell lines: MCF7 和 Ishikawa 细胞 Concentrations: 1000 nM Incubation Time: 8天 Method: MCF7和Ishikawa细胞在10%三倍活性炭处理的包含血清的培养基中生长3天。然后细胞以2,000细胞/孔的密度接种在96孔组织培养板,并按照指示每48小时处理一次。使用CellTiter-Glo发光细胞活性试剂盒根据制造商方案第一次处理后,第8天,进行细胞增殖试验 |
动物实验: |
Animal Models: 负荷 MCF-7 人乳腺肿瘤异种移植物的小鼠 Dosages: 8 mg/kg Administration: p.o. |
参考文献: |
1. Hurst RS, et al. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci, 2005, 25(17), 4396-4405. 2. Barron SC, et al. An allosteric modulator of alpha7 nicotinic receptors, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea (PNU-120596), causes conformational changes in the extracellular ligand binding domain similar to those caused by acetylcholine. Mol Pharmacol, 2009 76(2), 253-263. 3. Munro G, et al. The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU-120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat. Br J Pharmacol, 2012, doi: 10.1111/j.1476-5381.2012.02003.x |
溶解性: |
Soluble in DMSO |
保存条件: |
-20℃ |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
3.208 ml |
16.04 ml |
32.08 ml |
5 mM |
0.642 ml |
3.208 ml |
6.416 ml |
10 mM |
0.321 ml |
1.604 ml |
3.208 ml |
50 mM |
0.064 ml |
0.321 ml |
0.642 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |